Ventricular Tachycardia - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Ventricular Tachycardia - Pipeline Review, H1 2016', provides an overview of the Ventricular Tachycardia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia - The report reviews pipeline therapeutics for Ventricular Tachycardia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ventricular Tachycardia therapeutics and enlists all their major and minor projects - The report assesses Ventricular Tachycardia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ventricular Tachycardia Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ventricular Tachycardia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ventricular Tachycardia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ventricular Tachycardia Overview 6 Therapeutics Development 7 Pipeline Products for Ventricular Tachycardia - Overview 7 Ventricular Tachycardia - Therapeutics under Development by Companies 8 Ventricular Tachycardia - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Ventricular Tachycardia - Products under Development by Companies 11 Ventricular Tachycardia - Companies Involved in Therapeutics Development 12 Audentes Therapeutics, Inc. 12 Gilead Sciences, Inc. 13 HUYA Bioscience International, LLC 14 Milestone Pharmaceuticals, Inc. 15 Perrigo Company Plc 16 Ventricular Tachycardia - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 aladorian sodium - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 AT-307 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 eleclazine - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 etripamil - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 GS-967 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 HBI-3000 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 landiolol - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Ventricular Tachycardia - Recent Pipeline Updates 35 Ventricular Tachycardia - Dormant Projects 37 Ventricular Tachycardia - Product Development Milestones 38 Featured News & Press Releases 38 Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia 38 Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND 38 Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 39 May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 39 Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017 40 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Ventricular Tachycardia, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Ventricular Tachycardia - Pipeline by Audentes Therapeutics, Inc., H1 2016 12 Ventricular Tachycardia - Pipeline by Gilead Sciences, Inc., H1 2016 13 Ventricular Tachycardia - Pipeline by HUYA Bioscience International, LLC, H1 2016 14 Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals, Inc., H1 2016 15 Ventricular Tachycardia - Pipeline by Perrigo Company Plc, H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 21 Number of Products by Stage and Route of Administration, H1 2016 23 Number of Products by Stage and Molecule Type, H1 2016 25 Ventricular Tachycardia Therapeutics - Recent Pipeline Updates, H1 2016 35 Ventricular Tachycardia - Dormant Projects, H1 2016 37
List of Figures
Number of Products under Development for Ventricular Tachycardia, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Assessment by Monotherapy Products, H1 2016 17 Number of Products by Top 10 Targets, H1 2016 18 Number of Products by Stage and Top 10 Targets, H1 2016 18 Number of Products by Mechanism of Actions, H1 2016 20 Number of Products by Stage and Mechanism of Actions, H1 2016 20 Number of Products by Routes of Administration, H1 2016 22 Number of Products by Stage and Routes of Administration, H1 2016 22 Number of Products by Molecule Types, H1 2016 24 Number of Products by Stage and Molecule Types, H1 2016 24
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliabRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.